New SKYTyphoid™ vaccine receives prequalification from World Health Organization
Global health leaders are aggressively improving access to new vaccines to combat the estimated 11 to 20 million typhoid fever cases and 120,000 deaths each year. SK bioscience’s SKYTyphoid™ typhoid conjugate vaccine has received prequalification from the World Health Organization, offering a safe and effective option for infants and young children. With significant outbreaks in sub-Saharan Africa and the first locally acquired case in Taiwan, the need for improved vaccines is evident.
New Typhoid Conjugate Vaccine Receives WHO Prequalification
The recent prequalification of the new typhoid conjugate vaccine, SKYTyphoid™, by the World Health Organization (WHO) marks a pivotal moment in global health, opening the doors for public procurement of the vaccine by UN organizations. Developed through collaboration and with funding support, SKYTyphoid™ represents a significant advancement in typhoid prevention, offering a safe and effective solution for infants and young children. The achievement of WHO prequalification for SKYTyphoid™ marks a significant step forward in global health, offering a promising solution for the prevention of typhoid and contributing to the accessibility of life-saving vaccines for vulnerable populations worldwide.